Recent Finacing
Recent Raise
NRG Therapeutics develops orally bioavailable, CNS-penetrant small‑molecule inhibitors of the mitochondrial permeability transition pore (mPTP) to protect neurons and reduce neuroinflammation in Parkinson’s and ALS/MND.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at NRG Therapeutics.
